By Ian Walker

Shares of GENinCode rose 17% after the company said that it has filed a premarket notification with the U.S. Food and Drug Administration for its coronary heart disease risk assessment test kit, Cardio inCode-Score.

Shares at 1106 GMT were up 2.0 pence at 13.50 pence.

The London-listed predictive genetics company said Wednesday that approval will enable the expansion and commercial distribution of the device in the U.S.

It expects to receive FDA approval for the device over the next six months.

Write to Ian Walker at ian.walker@wsj.com

(END) Dow Jones Newswires

August 16, 2023 07:26 ET (11:26 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Grafico Azioni Genincode (LSE:GENI)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di Genincode
Grafico Azioni Genincode (LSE:GENI)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di Genincode